Macro Group Pharma returned to the green with a net income of EGP 22 mn in 1Q 2025, swinging from a net loss of EGP 78 mn in the same quarter last year, according to the company’s latest earnings release (pdf). “This performance reflects a tangible rebound in demand and the success of our disciplined cost management,” said Chairman Ahmed Elnayeb.

Revenues grew 210% y-o-y to EGP 184 mn during the quarter on the back of a 209% jump on sales volumes, totalling 3.8 mn units. Exports increased some 32x to EGP 5.5 mn — to now represent 3% of revenues — as part of its international expansion strategy that will “begin delivering results from 2Q25 onwards,” according to Elnayeb.

Looking ahead: “Our focus remains on scaling volumes, driving revenue growth, and reinforcing profitability. We will continue to capitalize on our strong brand equity and market position to introduce innovative products tailored to evolving consumer preferences,” said Elnayeb.

Tags: